Lanzhou

This research aims to evaluate how the medicine nerandomilast affects lung fibrosis in adults with systemic autoimmune rheumatic diseases who have lung fibrosis. The study includes adults 18 years and older who have not shown improvement in lung function after standard immunosuppressant treatment. Participants have interstitial lung disease related to rheumatic diseases such as rheumatoid arthritis, systemic sclerosis, idiopathic inflammatory myopathy, Sjgrens disease, or mixed connective tissue disease. Participants are randomly divided into two groups one group receives nerandomilast tablets and the other receives placebo tablets that look identical but contain no medicine. Tablets are taken twice daily for at least 26 weeks and up to 1 year. Participants continue their usual immunosuppressant treatments during the study. Participants stay in the study for about 7.5 to 13 months and visit the study site 9 to 10 times. During visits, lung function tests and chest imaging are performed, and participants complete questionnaires about symptoms and quality of life. Researchers compare results between the groups to assess the effects of nerandomilast while monitoring health and any side effects throughout the study.

Researchers are establishing a nationwide prospective database of diabetes patients treated at National Metabolic Management Centers MMCs across China. The study aims to explore epidemiology, genetics, biomarkers, risk factors, and prognostic methods related to diabetes and its complications, as well as other metabolic diseases. It also evaluates current care status, treatment strategies, patient costs, and quality of life to support the Healthy China 2030 strategy. Participants receive standard diabetes management at MMCs, which integrate advanced medical equipment and Internet of Things technology to provide a standardized, convenient, and precise model of care. After a comprehensive baseline evaluation, patients are followed with clinical and laboratory visits every 3 to 6 months based on individualized treatment plans, with yearly comprehensive assessments for glycemic control, risk factors, safety, and diabetes complications. During the study, participants undergo regular clinical and laboratory evaluations including monitoring of blood glucose, blood pressure, lipids, body mass index, and visceral fat. Researchers also assess health-related quality of life, cognitive function, psychological well-being, and cost-effectiveness. The study tracks diabetes-related clinical endpoints such as macrovascular and microvascular morbidity, mortality, infections, heart failure, neuropathy, and cancers, with follow-up lasting up to 20 years.

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and cardiovascular disease but no history of heart failure. The study aims to assess whether this combination can help reduce cardiovascular risks compared to a placebo with empagliflozin. This Phase III trial involves adults with these conditions who are already receiving treatment for them. Participants are randomly assigned to one of two groups. One group takes vicadrostat and empagliflozin tablets daily, while the other group takes placebo tablets that look like vicadrostat but have no active medicine, alongside empagliflozin. Treatment lasts from two and a half years up to four years and three months. All participants continue their usual medications for diabetes, blood pressure, and heart disease during the study. Throughout the study, lasting up to four years and three months, participants visit the study site regularly for health checks and blood samples. Doctors monitor cardiovascular events and any side effects experienced. The main outcome measured is the time until the first cardiovascular death or heart failure event. Other health indicators like blood pressure and kidney function are also tracked to understand the effects of the treatment combination.

Osteopenia is a condition marked by low bone density that can lead to osteoporosis and increased risk of fractures, especially in older women. This research investigates the impact of high-intensity interval training HIIT on bone health and related outcomes in Hong Kong Chinese women aged 60 to 74. The trial aims to address challenges older adults face with traditional exercise programs, such as the need for special equipment and low motivation, by testing a 24-week HIIT program. Participants will be randomly assigned to one of two groups a HIIT exercise group or a non-exercise control group attending recreational workshops. The HIIT program involves twice-weekly sessions over 24 weeks, each lasting 37 to 40 minutes, including warm-up, main exercise with high-impact weight-bearing activities, and cool down. The exercise intensity and complexity progress during the study, with safety measures like chair assistance and added weights in later weeks. Throughout the trial, participants will undergo assessments at three points before the intervention, immediately after 24 weeks, and six months after completion. Measures include bone mineral density, bone turnover markers, physical fitness parameters such as muscle strength and aerobic endurance, fear of falling, and quality of life. This comprehensive evaluation helps researchers understand the effects of HIIT on bone health and overall well-being in older women with osteopenia.

Researchers are investigating how well the drug VITRAKVI generic name larotrectinib works and how well patients tolerate it in real-world use for those with TRK fusion cancer. This cancer type involves a genetic change called an NTRK gene fusion that can cause tumors to grow. The study includes adults and children with locally advanced or metastatic solid tumors that have this specific gene fusion, reflecting a variety of common and rare cancers. Patients enrolled in this observational study are those for whom their doctors have decided to treat with larotrectinib. Treatments and medical care follow local standard practices without interference from the study. Participants are grouped based on cancer types like gastrointestinal, head and neck, soft tissue sarcoma, CNS, lung, melanoma, pediatric tumors, and others. Data on treatments, other medications, disease changes, and health symptoms will be collected during routine care. Participants will be observed for 24 to 60 months. Researchers will collect information on treatment side effects up to 30 days after treatment ends and monitor responses, disease control, survival, doses, and developmental milestones for up to 8 years. Medical records, including height, weight, neurological assessments, and Tanner stage will be reviewed as part of this long-term observation.